Compare DexCom, Inc. (DXCM) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs SAP SE — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while SAP SE trades at $214.78 (market cap $238.67B). The key difference: SAP SE is far larger — about 7.5× DexCom, Inc.'s market cap, and SAP SE pays a 1.38% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and SAP SE for 118 Days on average.
| DXCM | SAP | |
|---|---|---|
Market Cap | $31.86B | $238.67B |
Volume | 3,607,070 | 2,252,662 |
Sector | Health | Technology |
52-Week High | $92.34 | $280.46 |
52-Week Low | $54.84 | $146.38 |
Typical Hold Time | 62 Days | 118 Days |
Enterprise Value | $31.32B | $237.42B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
SAP trades at $212.40, up 1.08% today, with a bullish technical signal from moving averages and strong support at $208. The company reported robust 2025 results with revenue of $36.80B and net income of $7.16B, though Q2 2026 EPS missed expectations. Analyst consensus is a Buy with a $253.40 price target, reflecting optimism in cloud and AI initiatives.
Outlook remains positive driven by cloud revenue growth and AI integration, but risks include competitive pressures and execution challenges. The stock offers upside to consensus targets if margin expansion and deal momentum continue, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
